ProFactor Pharma
ProFactor Pharma Ltd (PFP) is a UK biotech company dedicated to transforming treatment availability for Haemophilia A patients by developing low-cost, high-yield recombinant Factor VIII (FVIII) products. The company focuses on manufacturing affordable, innovative therapies to serve the large, undertreated patient population worldwide, especially in emerging markets. PFP's mission is to provide accessible treatment options, leveraging proprietary technology and strategic partnerships, to address the significant unmet needs in haemophilia care globally.
Industries
Nr. of Employees
small (1-50)
ProFactor Pharma
C/O Ingenza Limited, Moubray Building, Edinburgh Technopol, Milton Bridge, EH26 0GB Penicuik, United Kingdom
Products
Standard half-life recombinant Factor VIII (rhFVIII)
A standard half-life recombinant Factor VIII therapeutic candidate produced from a high-yield mammalian cell line and optimised bioprocess, intended for replacement therapy in Haemophilia A.
Enhanced half-life recombinant Factor VIII (engineered rhFVIII)
A sequence-engineered recombinant Factor VIII candidate with DNA modifications intended to increase circulating half-life; currently in preclinical proof-of-concept testing.
Standard half-life recombinant Factor VIII (rhFVIII)
A standard half-life recombinant Factor VIII therapeutic candidate produced from a high-yield mammalian cell line and optimised bioprocess, intended for replacement therapy in Haemophilia A.
Enhanced half-life recombinant Factor VIII (engineered rhFVIII)
A sequence-engineered recombinant Factor VIII candidate with DNA modifications intended to increase circulating half-life; currently in preclinical proof-of-concept testing.
Services
Upstream and downstream process development for recombinant protein production, including single-use bioprocess implementation and scale-up support.
Development of high-expressing stable mammalian cell lines and generation of GMP-compliant Master and Working Cell Banks.
Execution of preclinical proof-of-concept studies and toxicology studies to support regulatory submissions for first-in-human trials.
Structural and functional characterisation services to demonstrate comparability with marketed reference products.
Transfer of developed processes to contract manufacturing organisations for scale manufacturing runs and supply of clinical/commercial material.
Preparation of IP filings and regulatory engagement strategy to support clinical entry and commercialisation.
Upstream and downstream process development for recombinant protein production, including single-use bioprocess implementation and scale-up support.
Development of high-expressing stable mammalian cell lines and generation of GMP-compliant Master and Working Cell Banks.
Execution of preclinical proof-of-concept studies and toxicology studies to support regulatory submissions for first-in-human trials.
Structural and functional characterisation services to demonstrate comparability with marketed reference products.
Transfer of developed processes to contract manufacturing organisations for scale manufacturing runs and supply of clinical/commercial material.
Preparation of IP filings and regulatory engagement strategy to support clinical entry and commercialisation.
Expertise Areas
- Biologics manufacturing and bioprocessing (CMC)
- Mammalian cell-line development
- Protein engineering and half-life extension
- Upstream fermentation and single-use bioprocessing
Key Technologies
- CHO-based mammalian expression
- Codon optimisation / sequence engineering
- Single-use disposable bioreactors
- Upstream fermentation optimisation
News & Updates
ProFactor Pharma Ltd. has been awarded a SMART: SCOTLAND grant to perform a preclinical Proof-of-Concept study of a novel approach to significantly improve the half-life of recombinant human Factor VIII (rhFVIII).
ProFactor Pharma participated in the global event to promote access and treatment for bleeding disorders, emphasizing the need for affordable and accessible haemophilia treatments.
Eugenia Wachters joined PFP as COO to lead business operations and develop commercial strategies for bringing FVIII treatments to underserved markets.
PFP completed a funding round to progress its clinical stage Recombinant Human Factor VIII to market and engage in licensing opportunities.
The company has optimised its process for manufacturing recombinant FVIII, achieving high yields and low-cost production to address the global unmet need.
ProFactor Pharma Ltd. has been awarded a SMART: SCOTLAND grant to perform a preclinical Proof-of-Concept study of a novel approach to significantly improve the half-life of recombinant human Factor VIII (rhFVIII).
ProFactor Pharma participated in the global event to promote access and treatment for bleeding disorders, emphasizing the need for affordable and accessible haemophilia treatments.
Eugenia Wachters joined PFP as COO to lead business operations and develop commercial strategies for bringing FVIII treatments to underserved markets.
PFP completed a funding round to progress its clinical stage Recombinant Human Factor VIII to market and engage in licensing opportunities.
The company has optimised its process for manufacturing recombinant FVIII, achieving high yields and low-cost production to address the global unmet need.